Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [4] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.

2024年5月16日 · IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response.

IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer...

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease...

2024年7月12日 · What is tarlatamab? Tarlatamab is used to treat non-small cell lung cancer in adults who are no longer responding to platinum-based chemotherapy. Tarlatamab is used when the cancer has progressed or has spread to other parts of the body (metastatic). Tarlatamab may also be used for purposes not listed in this medication guide.

IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Tarlatamab-dlle is approved to treat: Small cell lung cancer. It is used in adults with extensive-stage cancer that got worse during or after treatment with platinum-based chemotherapy. Tarlatamab-dlle is approved under FDA’s Accelerated Approval Program.

2024年7月18日 · Imdelltra (tarlatamab) is an immunotherapy treatment that may be used to treat adults with extensive-stage small cell lung cancer (ES-SCLC) which has progressed after receiving platinum-based chemotherapy.

2023年12月1日 · Tarlatamab is a type of immunotherapy known as a bispecific T-cell engager, or BiTE. These two-armed drugs simultaneously latch onto tumor cells and immune cells called T cells. By bringing T cells and cancer cells close together, they help the T cell recognize and destroy the cancer cell.

2024年7月10日 · Withhold tarlatamab-dlle or permanently discontinue based on severity. Cytopenias. Tarlatamab-dlle can cause cytopenias including neutropenia, thrombocytopenia, and anemia. In the pooled safety population, decreased neutrophils occurred in 12%, including 6% Grade 3 or 4, of tarlatamab-dlle-treated patients.